Michael Yu, Innovent CEO (Anthony Kwan/Bloomberg via Getty Images)

Chi­na ap­proves BC­MA CAR-T ther­a­py for mul­ti­ple myelo­ma, with In­novent beat­ing Leg­end in race to be first

In­novent and IA­SO Bio re­ceived the first ap­proval in Chi­na for a CAR-T ther­a­py for mul­ti­ple myelo­ma.

The ther­a­py, known as eque­cab­ta­gene au­toleu­cel, will be mar­ket­ed as Fu­ca­so, In­novent an­nounced Sun­day. It is in­di­cat­ed for pa­tients with mul­ti­ple myelo­ma that has re­turned or pro­gressed af­ter at least three pre­vi­ous treat­ments, in­clud­ing with a pro­tea­some in­hibitor and an im­munomod­u­la­to­ry drug.

In clin­i­cal tri­als, about three-quar­ters of the 101 evalu­able pa­tients went in­to re­mis­sion af­ter re­ceiv­ing the CAR-T ther­a­py. At one year, the pro­gres­sion-free sur­vival rate was 78.8%. One pa­tient ex­pe­ri­enced grade 3 cy­tokine re­lease syn­drome — an im­mune storm that hap­pens in re­ac­tion to CAR-T treat­ment — and two ex­pe­ri­enced grade 1 or 2 ICANS — neu­ro­tox­i­c­i­ty al­so re­lat­ed to CAR-T treat­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA